


Claims

1 A fused bicyclic pyrimidine derivative represented by the following general formula (1), or a salt thereof:




5 wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen
10 atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen
15 atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent (a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆
20 alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, a C₁ to C₆

alkylsulfonyl group, an amino group, a mono- or di-substituted
C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group,
a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆
alkylsulfonylamino group, an oxo group, a 6-membered aromatic
5 heterocyclic group, and a substituent represented by the
following formula:




wherein the ring D is a 3- to 7-membered nonaromatic
heterocyclic ring, which may contain, aside from the nitrogen
10 atom, 1 to 3 heteroatoms selected from the group consisting of
a nitrogen atom, a sulfur atom, and an oxygen atom and may
further contain 1 or 2 oxo-substituted carbon atoms);

R is a hydrogen atom, a C₁ to C₆ alkyl group, a C₁ to C₆
alkylcarbonyl group, or a C₁ to C₆ alkylsulfonyl group;

15 m is 1 or 2; and

n is 2 or 3.

2. The fused bicyclic pyrimidine derivative according to
claim 1 represented by the following general formula (1a), or
20 a salt thereof:




wherein the ring A is a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent (a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, a C₁ to C₆ alkylsulfonyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆


alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:



5 wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms);


10 R is a hydrogen atom, a C₁ to C₆ alkyl group, a C₁ to C₆ alkylcarbonyl group, or a C₁ to C₆ alkylsulfonyl group; and
 n is 2 or 3.

3. The fused bicyclic pyrimidine derivative according to
 15 claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is represented by the following formula:



 wherein R¹ is a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆
 20 alkoxycarbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxycarbonylamino group,


a C₁ to C₆ alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, or a substituent represented by the following formula:



5 wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms.

10


4. The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is represented by the following formula:



15 wherein X is -O- or -S(O)_q-; and q is 0, 1, or 2.

5. The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is a group represented by the following

20 formula:



claim 7, or a salt thereof, wherein in the general formula (1a), R is a hydrogen atom, and n is 3.

10. A tachykinin receptor antagonist containing as an active
5 ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 9, or a salt thereof.

11. An NK1 receptor antagonist containing as an active
ingredient the fused bicyclic pyrimidine derivative according
10 to any one of claims 1 through 9, or a salt thereof.

12. A prophylactic or therapeutic agent for dysuria,
including defective bladder functions such as increased
urinary frequency and incontinence of urine, containing as an
15 active ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 9, or a salt thereof.

13. A prophylactic or therapeutic agent for disorders of
digestive tract such as ulcerative colitis and Crohn's disease,
20 containing as an active ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 9, or a salt thereof.

14. A prophylactic or therapeutic agent for vomiting induced
25 by exposure to X-ray, chemotherapy, pregnancy, migraine,

postoperative pains, decreased gastrointestinal motility, and side effects of drugs, containing as an active ingredient the fused bicyclic pyrimidine derivative according to any one of claims 1 through 9, or a salt thereof.

5

15. A therapeutic agent for treating conditions, such as asthma, coughing, ache, migraine, tooth pain, and rheumatoid arthritis, containing as an active ingredient the fused bicyclic pyrimidine derivative according to any one of claims
10 1 through 9, or a salt thereof.